Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital
JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions”...
FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...
Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park
Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...
Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...
Hong Kong Researchers Identify New Target for Epilepsy Treatment
Researchers at the University of Hong Kong have published the results of a study that...
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...
Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline
Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...
NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...
I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...
Alibaba Health Reports 22.9% Revenue Growth in H1 2022
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...
3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...
China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau
China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round
China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...
Ascentage Pharma Receives Drug Production License for Suzhou Plant
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...